Breast Cancer Survivor Questions FDA Decision on Her ‘Miracle’ Drug

Thursday, June 30, 2011

After an emotional and tense two-day hearing in Silver Springs, Maryland, federal advisers voted to revoke the approval of the world’s top-selling cancer drug Avastin as a treatment for women with advanced breast cancer. The Food and Drug Administration’s Oncologic Drugs Advisory Committee heard from patients who say Avastin is a miracle drug, and from cancer advocates who point to adverse side-effects in other users. Finally, the committee concluded that research showed that the drug, which costs $88,000 a year per patient, failed to significantly extend patients’ lives or their quality of life. 

Heraleen Broome, from Oakland, Calif., has been taking Avastin for eight years, and testified at the hearing. She says the decision is tantamount to issuing her with a "license to die."


Heraleen Broome

Produced by:

Duncan Wilson

Leave a Comment

Register for your own account so you can vote on comments, save your favorites, and more. Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm your comments. Names are displayed with all comments. We reserve the right to edit any comments posted on this site. Please read the Comment Guidelines before posting. By leaving a comment, you agree to New York Public Radio's Privacy Policy and Terms Of Use.